@techreport{oai:mie-u.repo.nii.ac.jp:00008061,
 author = {楠, 正人 and Kusunoki, Masato and 田中, 光司 and Tanaka, Koji and 井上, 靖浩 and 内田, 恵一 and Ucida, Keiichi and 奥川, 喜永 and Okugawa, Yoshinaga and 荒木, 俊光 and Araki, Toshimitu},
 month = {May},
 note = {application/pdf, マウスIBDモデルの大腸の炎症と薬物(infliximab: IFXとtacrolimus : FK506)による治療効果を病理組織学的生体内可視化し形態学的に解析する。陰窩内白血球浸潤数と陰窩欠損数はIFX投与群で各々減少していた。陰窩上皮細胞は、管腔側で一部脱落欠損や全欠損が観察できた。陰窩の長さはIFX投与後群で回復が早かった。陰窩底部から管腔側に向かう再生上皮の継時的変化は観察できなかった。FK506投与群はIFX投与群とほぼ同様であった。蛍光標識抗TNF-α抗体は粘膜固有層、粘膜下層への集積や後毛細管細静脈内皮に接着している白血球や陰窩内浸潤白血球表面への結合が可視化できた。, We attempted to visualize in vivo therapeutic response of infliximab (IFX) and tacrolimus (FK506) in the murine IBD model using two photon laser scanning microscopy and to analyze their histopathological response morphologically. The number of leukocyte infiltrates within the crypt and the number of crypt loss were decreased in IFX-treated mice. The length of colonic crypt was increased in IFX-treated mice. Serial change in regenerative epithelial cells was not observed. The findings in FK506-treated mice were similar to those in IFX-treated mice. The fluorescence labeled anti-TNF-alpha antibody was observed in the mucosal stroma, suggesting the binding of labeled antibodies with free TNF-alpha. It was also observed in the surface of leukocytes within the postcapillary venules or those infiltrating into the damaged crypt, suggesting the binding of labeled antibodies with the membrane binding TNF- alpha of the surface TNF- alpha producing leukocytes., 2012年度～2013年度科学研究費補助金(挑戦的萌芽研究)研究成果報告書, 24659588},
 title = {二光子レーザー顕微鏡を用いた炎症性腸疾患モデルの生体内消化管全層解析と病態解明},
 year = {2014}
}